share_log

裕承科金：董事名單與其角色和職能

ARTA TECHFIN: List of Directors and their Role and Function

香港交易所 ·  Jan 2 09:43
Summary by Moomoo AI
裕承科金有限公司（「ARTA TECHFIN」）近日公布了其董事會成員名單及各成員在董事會下屬委員會中的角色和職能。執行董事包括行政總裁許昊先生和首席財務總監李楚楚女士。非執行董事為鄭志剛博士SBS, JP和韓金樑先生，而獨立非執行董事則包括凌潔心女士、盧震宇先生和譚麗芬醫生。凌潔心女士擔任審核委員會和提名委員會的主席，而譚麗芬醫生則是薪酬委員會的主席。該安排自2024年1月2日起生效。
裕承科金有限公司（「ARTA TECHFIN」）近日公布了其董事會成員名單及各成員在董事會下屬委員會中的角色和職能。執行董事包括行政總裁許昊先生和首席財務總監李楚楚女士。非執行董事為鄭志剛博士SBS, JP和韓金樑先生，而獨立非執行董事則包括凌潔心女士、盧震宇先生和譚麗芬醫生。凌潔心女士擔任審核委員會和提名委員會的主席，而譚麗芬醫生則是薪酬委員會的主席。該安排自2024年1月2日起生效。
YU CHENG TECHNOLOGY CO., LTD. (“ARTA TECHFIN”) RECENTLY ANNOUNCED ITS LIST OF BOARD MEMBERS AND THE ROLES AND FUNCTIONS OF EACH MEMBER IN THE SUBORDINATE COMMITTEES OF THE BOARD OF DIRECTORS. The Executive Directors include Mr. Xu Hao, Chief Executive Officer, and Ms. Li Chuchu, Chief Financial Officer. The non-executive directors are Dr Zheng Chi Kong SBS, JP and Mr Han Jin Leung, while the independent non-executive directors include Ms Ling Jie Shun, Mr Lu Zhen Yu and Dr Tam Lifan. Ms. Ling Chien serves as Chair of the Audit Committee and Nominating Committee, while Dr. Tam Lifen is Chair of the Remuneration Committee. The arrangement will take effect from 2 January 2024.
YU CHENG TECHNOLOGY CO., LTD. (“ARTA TECHFIN”) RECENTLY ANNOUNCED ITS LIST OF BOARD MEMBERS AND THE ROLES AND FUNCTIONS OF EACH MEMBER IN THE SUBORDINATE COMMITTEES OF THE BOARD OF DIRECTORS. The Executive Directors include Mr. Xu Hao, Chief Executive Officer, and Ms. Li Chuchu, Chief Financial Officer. The non-executive directors are Dr Zheng Chi Kong SBS, JP and Mr Han Jin Leung, while the independent non-executive directors include Ms Ling Jie Shun, Mr Lu Zhen Yu and Dr Tam Lifan. Ms. Ling Chien serves as Chair of the Audit Committee and Nominating Committee, while Dr. Tam Lifen is Chair of the Remuneration Committee. The arrangement will take effect from 2 January 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more